Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2010 | 1 |
2013 | 1 |
2014 | 1 |
2016 | 2 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
The following terms were ignored: "", OR
Quoted phrases not found in phrase index: "941690-55-7"
Page 1
The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.
J Clin Psychopharmacol. 2014 Apr;34(2):199-204. doi: 10.1097/JCP.0000000000000071.
J Clin Psychopharmacol. 2014.
PMID: 24525659
Clinical Trial.
This study investigates the efficacy, tolerability, and cognitive effects of AZD2624, a selective, orally active NK(3) receptor antagonist, in symptomatic patients with schizophrenia. ...Results of the trial do not support a role for the NK(3) antagonist AZD2624 as …
This study investigates the efficacy, tolerability, and cognitive effects of AZD2624, a selective, orally active NK(3) receptor antag …
In vitro assessment of metabolic drug-drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies.
Li Y, Zhou D, Ferguson SS, Dorff P, Simpson TR, Grimm SW.
Li Y, et al.
Xenobiotica. 2010 Nov;40(11):721-9. doi: 10.3109/00498254.2010.512670.
Xenobiotica. 2010.
PMID: 20937004
No time-dependent inactivation of CYP3A4/5 activity (midazolam 1'-hydroxylation) by AZD2624 was observed. AZD2624 demonstrated weak to no inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. AZD2624 was not an inducer of CYP1A2 or CYP2B6. Althou …
No time-dependent inactivation of CYP3A4/5 activity (midazolam 1'-hydroxylation) by AZD2624 was observed. AZD2624 demonstrated …
Item in Clipboard
Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial.
George JT, Kakkar R, Marshall J, Scott ML, Finkelman RD, Ho TW, Veldhuis J, Skorupskaite K, Anderson RA, McIntosh S, Webber L.
George JT, et al.
J Clin Endocrinol Metab. 2016 Nov;101(11):4313-4321. doi: 10.1210/jc.2016-1202. Epub 2016 Jul 26.
J Clin Endocrinol Metab. 2016.
PMID: 27459523
Clinical Trial.
Item in Clipboard
A rapid alternative to X-ray crystallography for chiral determination: case studies of vibrational circular dichroism (VCD) to advance drug discovery projects.
Wesolowski SS, Pivonka DE.
Wesolowski SS, et al.
Bioorg Med Chem Lett. 2013 Jul 15;23(14):4019-25. doi: 10.1016/j.bmcl.2013.05.005. Epub 2013 May 9.
Bioorg Med Chem Lett. 2013.
PMID: 23743289
Free article.
Item in Clipboard
Population Pharmacokinetic and Pharmacodynamic Modeling of AZD4901 and Simulation to Support Dose Selection for the Phase 2a Study.
Xu H, Li J, Webber L, Kakkar R, Chen Y, Al-Huniti N.
Xu H, et al.
J Clin Pharmacol. 2016 Aug;56(8):999-1008. doi: 10.1002/jcph.680. Epub 2016 Jan 18.
J Clin Pharmacol. 2016.
PMID: 26626581
Clinical Trial.
Item in Clipboard
Cite
Cite